Technical Analysis for IDRA - Idera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 3.17 5.67% 0.17
IDRA closed up 5.67 percent on Friday, September 13, 2019, on 81 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical IDRA trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 200 DMA Bearish 5.67%
Upper Bollinger Band Walk Strength 5.67%
Wide Bands Range Expansion 5.67%
Jack-in-the-Box Bullish Bullish Swing Setup 1.60%
Upper Bollinger Band Walk Strength 1.60%
Inside Day Range Contraction 1.60%
Wide Bands Range Expansion 1.60%
Overbought Stochastic Strength 1.60%

Older signals for IDRA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. The company's cancer program comprises IMO-2055, which has completed Phase Ib clinical trials for treatment of non-small cell lung cancer; and has completed Phase II clinical trials for the treatment of squamous cell, head and neck, and colorectal cancer. It is also developing IMO-2134 that has completed Phase I clinical trials to treat asthma and allergy. In addition, the company's research candidates include IMO-4200 for hematologic malignancies; and TLR3 Agonists for infectious diseases and other applications, as well as gene silencing oligonucleotides for inhibition of gene expression by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
Biotechnology Health Cancer Biology Infectious Diseases Treatment Of Cancer Clinical Trial Alzheimer's Disease Non Small Cell Lung Cancer Genetics Psoriasis Gene Expression Asthma Allergy Colorectal Cancer Autoimmune And Inflammatory Diseases Hematologic Malignancies RNA Treatment Of Non Small Cell Lung Cancer Treatment Of Autoimmune And Inflammatory Diseases United Nations Treatment Of Psoriasis Gene Silencing Tlr7 Tlr9 Vaccine Products
Is IDRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.1
52 Week Low 2.08
Average Volume 194,368
200-Day Moving Average 2.9884
50-Day Moving Average 2.5326
20-Day Moving Average 2.564
10-Day Moving Average 2.849
Average True Range 0.2476
ADX 34.68
+DI 34.9641
-DI 11.0255
Chandelier Exit (Long, 3 ATRs ) 2.8372
Chandelier Exit (Short, 3 ATRs ) 2.8228
Upper Bollinger Band 3.3123
Lower Bollinger Band 1.8157
Percent B (%b) 0.9
BandWidth 58.369735
MACD Line 0.1856
MACD Signal Line 0.0947
MACD Histogram 0.0909
Fundamentals Value
Market Cap 474.32 Million
Num Shares 150 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -9.32
Price-to-Sales 13.60
Price-to-Book 2.94
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.53
Resistance 3 (R3) 3.50 3.35 3.47
Resistance 2 (R2) 3.35 3.26 3.37 3.45
Resistance 1 (R1) 3.26 3.20 3.31 3.29 3.43
Pivot Point 3.11 3.11 3.13 3.13 3.11
Support 1 (S1) 3.02 3.02 3.07 3.05 2.91
Support 2 (S2) 2.87 2.96 2.89 2.89
Support 3 (S3) 2.78 2.87 2.87
Support 4 (S4) 2.81